Respira Therapeutics Inc, based in Albuquerque, NM, is a pioneering company focused on developing next-generation inhalation products for cardiopulmonary diseases. With their advanced particle engineering and formulation approaches, combined with proprietary device technologies, Respira aims to enhance drug delivery to the lung periphery, specifically targeting patients with pulmonary arterial hypertension (PAH). Their lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy designed to provide acute relief from the most common symptoms of breathlessness and fatigue.
With ongoing Phase 2 clinical trials for their pipeline candidate, Respira is at the forefront of respiratory treatment innovation. Their industry-leading experience and expertise are dedicated to developing therapeutic technology that may offer substantial new benefits for patients worldwide. Committed to patient well-being, Respira emphasizes the importance of genuine employment opportunities and warns against fraudulent job offers or financial commitments made by individuals falsely claiming to represent the company.
Generated from the website